PolarityTE Inc

NASDAQ:PTE  
0.52
-0.09 (-14.00%)
Products

PolarityTE Announces Submission Of Complete Response To FDA's Clinical Hold Correspondence For SkinTE Investigational New Drug Application

Published: 12/20/2021 13:17 GMT
PolarityTE Inc (PTE) - Polarityte Announces Submission of Complete Response to FDA's Clinical Hold Correspondence for Skinte® Investigational New Drug Application.
Polarityte Inc - Announces Submission of Complete Response to FDA's Clinical Hold Correspondence for Skinte® Investigational New Drug Application.
Polarityte Inc - Complete Response to Hold Issues Was Submitted on December 17, 2021.